Epigenomics AG (EPGNF)
OTCMKTS
· Delayed Price · Currency is USD
0.7896
+0.2896 (57.92%)
At close: Jun 25, 2024
Epigenomics AG Revenue
In the year 2024, Epigenomics AG had annual revenue of 94.00K EUR, down -72.29%. Epigenomics AG had revenue of 47.00K in the quarter ending December 31, 2024, a decrease of -31.00%.
Revenue
94.00K EUR
Revenue Growth
-98.14%
P/S Ratio
8.67
Revenue / Employee
15.67K EUR
Employees
6
Market Cap
843.49K USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 94.00K | -245.23K | -72.29% |
| Dec 31, 2023 | 339.23K | -559.77K | -62.27% |
| Dec 31, 2022 | 899.00K | -5.30M | -85.51% |
| Dec 31, 2021 | 6.20M | 5.36M | 636.70% |
| Dec 31, 2020 | 842.00K | -283.00K | -25.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |